# Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

> **NCT02523313** · PHASE2 · COMPLETED · sponsor: **Prof. Dr. med. Dirk Schadendorf** · enrollment: 167 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Nivolumab + Placebo
- **DRUG:** Nivolumab + Ipilimumab
- **DRUG:** Double Placebo Control

## Key facts

- **NCT ID:** NCT02523313
- **Lead sponsor:** Prof. Dr. med. Dirk Schadendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-02
- **Primary completion:** 2021-06-27
- **Final completion:** 2021-06-27
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02523313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02523313, "Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02523313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*